Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageExelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and regimens at the forefront of cancer care. We have produced four marketed pharmaceutical products, two of which are formulations of our flagship molecule, cabozantinib, and we are steadily advancing and evolving our product pipeline portfolio, including our lead clinical asset, zanzalintinib, currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of certain forms of colorectal cancer (CRC), as well as the focus of an extensive late-stage clinical development program in other indications.
In the company’s own words · 10-K filed Feb 10, 2026 · SEC EDGAR
Business segments
Q2 2026 · $930.6MThe company’s own SEC segment disclosure.
- Product Gross$812.8M87%
- License$59.8M6%
- Collaboration$55.7M6%
- Cometriq$2.4M0%
Exelixis, Inc. (EXEL) reported revenue of $611M in Q1 2026 (quarter ended April 3, 2026), up 10.0% from the same quarter a year earlier. That came with a gross margin of 97% and net income of $210M (34% of revenue). For the full year FY2025, revenue was $2.32B (+7.0% year on year) and net income $783M. Its largest product in 2026-Q2 was Product Gross at $813M, 87% of the disclosed total, just ahead of License at 6.4%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.